Biotest AG
BTTAY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 6.1% | 32.6% | 0.1% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 30.8% | 40.9% | 24.2% | 15.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | -$0 | -$0 |
| % Margin | 13% | 21% | -3.2% | -9.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 3.6% | 18.6% | -6.1% | -12.3% |
| EPS | 0.36 | 1.6 | -0.4 | -0.8 |
| % Growth | -77.5% | 500% | 50% | – |
| EPS Diluted | 0.36 | 1.6 | -0.4 | -0.8 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 16.6% | 26.6% | 4.8% | -3.5% |